// Copy of the liver content for quiz generation
export const liverContent = {
  "fileName": "Liver - Students",
  "processedAt": "2025-10-01T15:46:25.090Z",
  "slides": [
    {
      "slideNumber": 1,
      "title": "Liver Anatomy & Function",
      "keyPoints": [
        "Hepatocytes perform metabolic functions",
        "Portal circulation from GI tract",
        "Bile production and secretion"
      ],
      "drugReferences": [
        "Acetaminophen metabolism",
        "First-pass effect"
      ],
      "clinicalPearls": [
        "Liver disease affects drug clearance"
      ]
    },
    {
      "slideNumber": 2,
      "title": "Hepatic Drug Metabolism",
      "keyPoints": [
        "Phase I and Phase II reactions",
        "CYP450 enzyme system",
        "Drug interactions"
      ],
      "drugReferences": [
        "CYP3A4 substrates",
        "Warfarin interactions"
      ],
      "clinicalPearls": [
        "Genetic polymorphisms affect metabolism"
      ]
    },
    {
      "slideNumber": 3,
      "title": "Hepatotoxicity",
      "keyPoints": [
        "Drug-induced liver injury mechanisms",
        "Dose-dependent vs idiosyncratic reactions",
        "Monitoring liver function tests"
      ],
      "drugReferences": [
        "Acetaminophen overdose",
        "Statins and hepatotoxicity",
        "Isoniazid liver injury"
      ],
      "clinicalPearls": [
        "ALT/AST elevation patterns indicate injury type"
      ]
    },
    {
      "slideNumber": 4,
      "title": "Hepatic Impairment Dosing",
      "keyPoints": [
        "Child-Pugh classification system",
        "Dose adjustments for hepatic impairment",
        "Contraindicated medications"
      ],
      "drugReferences": [
        "Benzodiazepines in liver disease",
        "Opioids and hepatic metabolism",
        "Anticoagulants dose adjustments"
      ],
      "clinicalPearls": [
        "Albumin levels affect drug binding"
      ]
    }
  ],
  "pharmacologyTopics": [
    {
      "topic": "Hepatic Clearance",
      "description": "First-pass metabolism and bioavailability",
      "relevantDrugs": [
        "Propranolol",
        "Morphine",
        "Lidocaine"
      ],
      "clinicalSignificance": "High hepatic extraction ratio drugs"
    },
    {
      "topic": "CYP450 Interactions",
      "description": "Cytochrome P450 enzyme induction and inhibition",
      "relevantDrugs": [
        "Rifampin (inducer)",
        "Ketoconazole (inhibitor)",
        "Phenytoin (inducer)"
      ],
      "clinicalSignificance": "Major source of drug-drug interactions"
    },
    {
      "topic": "Hepatic Encephalopathy",
      "description": "Ammonia accumulation and CNS effects",
      "relevantDrugs": [
        "Lactulose",
        "Rifaximin",
        "L-ornithine L-aspartate"
      ],
      "clinicalSignificance": "Avoid sedatives and opioids"
    }
  ],
  "identifiedGaps": [
    "Missing information about hepatic impairment dosing guidelines",
    "No coverage of Child-Pugh classification scoring",
    "Limited discussion of drug-induced liver injury prevention",
    "Insufficient detail on alternative metabolism pathways"
  ]
}